Status -Model COVID-19/FLU -FDA EUA Visual Read Rapid Test
The only FDA EUA visual read rapid test for simultaneous detection and differential diagnosis of SARS-CoV-2, Influenza Type A & Influenza Type B Antigen in nasopharyngeal swab specimens.
Most popular related searches
sars-cov-2
COVID 19
type a influenza
influenza type
respiratory disease
nasopharyngeal swab
influenza b
influenza antigen
antigen specimen
Performance Characteristics
- COVID-19: Sensitivity 93.9%; Specificity 100%
- Flu A: Sensitivity 91.4%; Specificity 95.7%
- Flu B: Sensitivity 87.6%; Specificity 95.9%
Efficient
- 3 tests in 1 consolidates and speeds workflow
- Fast results in only 15 minutes
- Easy to run with no pipetting and premeasured buffer
- Room temperature storage
Convenient
- Generate revenue by processing results in-house
- Visual read removes capital equipment analyzer costs
- Collect 1 sample for both COVID-19, Flu A and Flu B
- Simplified “Go Live” with Chembio’s enhanced on site training program
